<strong>Rapporti</strong> <strong>ISTISAN</strong> <strong>09</strong>/<strong>17</strong> Ignatov A, Bartalini O, Bellini V, Bocquet JP, Calvat P, Capogni M, Casano M, Ghio FMA, Girolami B, et al. New experimental and simulated results on nuclear media effects in meson photoproduction off nuclei. Progress in particle and nuclear physics. 2008;61(1):253-9. Imperi M, Gherardi G, Pataracchia M, Baldassarri L, Facinelli B, Cardona F, Orefici G, Creti R. Fattori di virulenza, antibiotico resistenza ed epidemiologia molecolare di ceppi di S. dysgalactiae subsp. equisimilis da infezioni invasive, non invasive e da portatori [abstract]. Bollettino della SIM. 2008;10(1):28. Indovina P, Rainaldi G, Santini MT. Hypoxia increases adhesion and spreading of MG-63 threedimensional tumor spheroids. Anticancer research. 2008;28:1013-22. Iorio E, Glunde K, Takagy T, Ricci A, Pisanu ME, Canevari S, Bhujwalla Z, Podo F. Elevated choline kinase protein expression and activity correlate with increased MRS-detected phosphocholine levels in ovarian carcinomas [proceedings]. Proceedings on CD-ROM - International Society for Magnetic Resonance in Medicine. Scientific meeting and exhibition. 2008;16:247. Iorio E, Ricci A, Pisanu ME, Di Vito M, Canese R, Mezzanzanica D, Canevari S, Podo F. Phosphatidylcholine-specific phospholipase C contributes to the increase of phosphocholine in ovarian cancer cells [proceedings]. Proceedings on CD-ROM - International Society for Magnetic Resonance in Medicine. Scientific meeting and exhibition. 2008;16:245. Iorio E, Ricci A, Pisanu ME, Di Vito M, Castellano A, de Cecco L, Mezzanzanica D, Canevari S, Podo F. Biochemical and genomic characterization of enzymes contributing to phosphocholine MRS signal in ovary cancer [abstract]. Magma. 2008;21(Suppl 1):269. Iorio E, Testa C, Stringaro A, Condello M, Arancia G, Lococo E, Carnevale R, Lenti L, Strom R, Podo F. Effects of mitochondrial impairment on lipid metabolism monitored by NMR in intact HuT 78 lymphoblastoid cells [abstract]. Magnetic Resonance Materials in Physics, Biology and Medicine. 2008;21(Suppl. 1):269. Iorio E, Torosantucci A, Bromuro C, Chiani P, Ferretti A, Giannini M, Cassone A, Podo F. Candida albicans cell wall comprises a branched ß-D-(1-6)-glucan with ß-D-(1-3)-side chains. Carbohydrate research. 2008;343(6):1050-61. Jensen SB, Di Santo R, Olsen AK, Pedersen K, Costi R, Cirilli R, Cumming P. Synthesis and cerebral uptake of 1-(1-[(11)C]methyl-1H-pyrrol-2-yl)-2-phenyl-2-(1-pyrrolidinyl)ethanone, a novel tracer for positron emission tomography studies of monoamine oxidase type A. Journal of medicinal chemistry. 2008;51(6):16<strong>17</strong>-22. King LA, Levy-Bruhl D, O’Flanagan D, Bacci S, Lopalco P, Kudjawu Y, Salmaso S, VENICE country specific gate keepers and contact points. Introduction of human papillomavirus (HPV) vaccination into national immunisation schedules in Europe: results of the VENICE 2007 survey. Eurosurveillance. 2008;13(33):18954. Knellwolf AL, Deligne J, Chiarotti F, Auleley GR, Palmieri S, Boisgard Blum C, Panei P, Autret-Leca E. Prevalence and patterns of methylphenidate use in French children and adolescents. European journal of clinical pharmacology. 2008;64(3):311-7. Kremer JR, Brown KE, Jin L, Santibanez S, Sergey V, Shulga V, Magurano F, Fortuna C. High genetic diversity of measles virus, World Health Organization European Region, 2005-2006. Emerging infectious diseases. 2008;14(1):107-14. Krishnan A, Giuliani A, Tomita M. Evolution of gene regulatory networks: robustness as an emergent property of evolution. Physica A. 2008;387:2<strong>17</strong>0-86. 414
<strong>Rapporti</strong> <strong>ISTISAN</strong> <strong>09</strong>/<strong>17</strong> Krishnan A, Giuliani A, Zbilut JP, Tomita M. Implications from a network-based topological analysis of ubiquitin unfolding simulations. PLoS ONE. 2008;3(5):e2149. Krishnan A, Tomita M, Giuliani A. Evolution of gene regulatory networks: Robustness as an emergent property of evolution. Physica A. 2008;387:2<strong>17</strong>0-86. Krishnan A, Zbilut JP, Tomita M, Giuliani A. Proteins as networks: usefulness of graph theory in protein science. Current protein & peptide science. 2008;9(1):28-8. Kroneman A, Harris J, Vennema H, Duizer E, van Duynhoven Y, Gray JJ, Iturriza-Gómara M, Böttiger B, Falkenhorst G, Johnsen C, von Bonsdorff C, Maunula L, Kuusi M, Pothier P, Gallay A, Schreier E, Koch J, Szücs G, Reuter G, Krisztalovics K, Lynch M, McKeown P, Foley B, Coughlan S, Ruggeri FM, Di Bartolo I, Vainio K, Isakbaeva E, Poljsak-Prijatelj M, Hocevar Grom A, Bosch A, Buesa J, Sánchez- Fauquier A, Hernandéz-Pezzi G, Hedlund K-O, Koopmans M. Data quality of 5 years of central norovirus outbreak reporting in the European Network for food-borne viruses outbreak. Journal of public health. 2008;30(1):82-90. Kroneman A, Verhoef L, Harris J, Vennema H, Duizer E, van Duynhoven Y, Gray JJ, Iturriza-Gómara M, Böttiger B, Falkenhorst G, Johnsen C, von Bonsdorff C, Maunula L, Kuusi M, Pothier P, Gallay A, Schreier E, Koch J, Szücs G, Reuter G, Krisztalovics K, Lynch M, McKeown P, Foley B, Coughlan S, Ruggeri FM, Di Bartolo I, Vainio K, Isakbaeva E, Poljsak-Prijatelj M, Hocevar Grom A, Mijovski JZ, Bosch A, Buesa J, Sánchez-Fauquier A, Hernandéz-Pezzi G, Hedlund K-O, Koopmans M. Analysis of integrated virological and epidemiological reports of norovirus outbreaks collected within the foodborne viruses in Europe network from 1 July 2001 to 30 June 2006. Journal of clinical microbiology. 2008;46(9):2959-65. La Regina G, D’Auria FD, Tafi A, Piscitelli F, Olla S, Caporuscio F, Nencioni L, Cirilli R, La Torre F, Rodrigues De Melo N, Kelly SL, Lamb DC, Artico M, Botta M, Palamara AT, Silvestri R. 1-[(3- Aryloxy-3-aryl)propyl]-1H-imidazoles, new imidazoles with potent activity against Candida albicans and dermatophytes. Synthesis, structure-activity relationship, and molecular modeling studies. Journal of medicinal chemistry. 2008;51(13):3841-55. La Rocca C, Alivernini S, Badiali M, Cornoldi A, Iacovella N, Silvestroni L, Spera G, Turrio Baldassarri L. TEQs and body burden for PCDDs, PCDFs, and dioxin-like PCBs in human adipose tissue. Chemosphere. 2008;73(1):92-6. La Rosa G, Pourshaban M, Iaconelli M, Muscillo M. Recreational and drinking waters as a source of norovirus gastroenteritis outbreaks: a review and update. Environmental biotechnology. 2008;4(1):15-24. Labbaye C, Spinello I, Quaranta MT, Pelosi E, Pasquini L, Petrucci E, Biffoni M, Nuzzolo ER, Billi M, Foà R, Brunetti E, Grignani F, Testa U, Peschle C. A three-step pathway comprising PLZF/miR- 146a/CXCR4 controls megakaryopoiesis. Nature cell biology. 2008;10(7):788-801. Lagorio S, Grande E, Martina L. Rassegna degli studi epidemiologici sul rischio di tumori tra i militari della Guerra del Golfo e delle missioni nei Balcani. Epidemiologia e prevenzione. 2008;32(3):145-55. Lalosevic D, Lalosevic V, Klem I, Stanojev-Jovanovic D, Pozio E. Pulmonary capillariasis miming bronchial carcinoma. American journal of tropical medicine and hygiene. 2008;78(1):14-6. Lamagni T, Darenberg J, Luca-Harari B, Siljander T, Efstratiou A, Henriques-Normark B, Vuopio- Varkila J, Bouvet A, Creti R, Ekelund K, Koliou M, Reinert RR, Stathi A, Strakova L, Ungureanu V, Schalén C, Strep-EURO Study Group, Jasir A. Epidemiology of severe Streptococcus pyogenes disease in Europe. Journal of clinical microbiology. 2008;46(7):2359-67. Lamberti A, Baglio G, Binkin N, Cattaneo C, Fontana G, Perra A, Spinelli A. Sistema di indagini sui rischi comportamentali in età 6-<strong>17</strong> anni [abstract]. Panorama della sanità. 2008;36(Suppl):411. 415
- Page 1 and 2:
ISTITUTO SUPERIORE DI SANITÀ Relaz
- Page 3 and 4:
Rapporti ISTISAN 09/17 INDICE Lista
- Page 5 and 6:
Rapporti ISTISAN 09/17 Reparto Peri
- Page 7:
Rapporti ISTISAN 09/17 Registro naz
- Page 10 and 11:
viii
- Page 13 and 14:
Rapporti ISTISAN 09/17 PARTE 1 Quad
- Page 15 and 16:
Rapporti ISTISAN 09/17 EVOLUZIONE O
- Page 17 and 18:
Rapporti ISTISAN 09/17 Il fine ulti
- Page 19 and 20:
Rapporti ISTISAN 09/17 - Decreto Pr
- Page 21 and 22:
Rapporti ISTISAN 09/17 L’Istituto
- Page 23 and 24:
Rapporti ISTISAN 09/17 Per quanto r
- Page 25 and 26:
Rapporti ISTISAN 09/17 Nell’ambit
- Page 27 and 28:
Rapporti ISTISAN 09/17 europeo sull
- Page 29 and 30:
Rapporti ISTISAN 09/17 risvolti app
- Page 31 and 32:
Rapporti ISTISAN 09/17 alto di qual
- Page 33 and 34:
Rapporti ISTISAN 09/17 140 120 100
- Page 35 and 36:
Rapporti ISTISAN 09/17 7000 6171 60
- Page 37 and 38:
Rapporti ISTISAN 09/17 Nel 2005, la
- Page 39 and 40:
Rapporti ISTISAN 09/17 scientifico.
- Page 41 and 42:
Rapporti ISTISAN 09/17 500 477 450
- Page 43 and 44:
Rapporti ISTISAN 09/17 La missione
- Page 45 and 46:
Rapporti ISTISAN 09/17 L’offerta
- Page 47 and 48:
Rapporti ISTISAN 09/17 distanza sul
- Page 49 and 50:
Rapporti ISTISAN 09/17 risultati di
- Page 51 and 52:
Rapporti ISTISAN 09/17 revisionato
- Page 53 and 54:
Rapporti ISTISAN 09/17 valutazione
- Page 55 and 56:
Rapporti ISTISAN 09/17 Figura 8. Pa
- Page 57 and 58:
Rapporti ISTISAN 09/17 Libia Gestio
- Page 59 and 60:
Rapporti ISTISAN 09/17 PARTE 2 Atti
- Page 61 and 62:
Rapporti ISTISAN 09/17 DIPARTIMENTO
- Page 63 and 64:
Rapporti ISTISAN 09/17 Descrizione
- Page 65 and 66:
Rapporti ISTISAN 09/17 - validazion
- Page 67 and 68:
Rapporti ISTISAN 09/17 Reparto Qual
- Page 69 and 70:
Rapporti ISTISAN 09/17 DIPARTIMENTO
- Page 71 and 72:
Rapporti ISTISAN 09/17 in pazienti
- Page 73 and 74:
Rapporti ISTISAN 09/17 metabolico c
- Page 75 and 76:
Rapporti ISTISAN 09/17 suscettibile
- Page 77 and 78:
Rapporti ISTISAN 09/17 - Diagnostic
- Page 79 and 80:
Rapporti ISTISAN 09/17 sull’attiv
- Page 81 and 82:
Rapporti ISTISAN 09/17 - analisi de
- Page 83 and 84:
Rapporti ISTISAN 09/17 Reparto Meta
- Page 85 and 86:
Rapporti ISTISAN 09/17 confermando
- Page 87 and 88:
Rapporti ISTISAN 09/17 in un modell
- Page 89 and 90:
Rapporti ISTISAN 09/17 - studio sui
- Page 91 and 92:
Rapporti ISTISAN 09/17 effetti meti
- Page 93 and 94:
Rapporti ISTISAN 09/17 DIPARTIMENTO
- Page 95 and 96:
Rapporti ISTISAN 09/17 glioblastoma
- Page 97 and 98:
Rapporti ISTISAN 09/17 di cellule s
- Page 99 and 100:
Rapporti ISTISAN 09/17 Sono stati c
- Page 101 and 102:
Rapporti ISTISAN 09/17 documentato
- Page 103 and 104:
Rapporti ISTISAN 09/17 Per quanto r
- Page 105 and 106:
Rapporti ISTISAN 09/17 - Valutazion
- Page 107 and 108:
Rapporti ISTISAN 09/17 stato quello
- Page 109 and 110:
Rapporti ISTISAN 09/17 Altre attivi
- Page 111 and 112:
Rapporti ISTISAN 09/17 Attività is
- Page 113 and 114:
Rapporti ISTISAN 09/17 - Disregolaz
- Page 115 and 116:
Rapporti ISTISAN 09/17 Reparto Farm
- Page 117 and 118:
Rapporti ISTISAN 09/17 Attività is
- Page 119 and 120:
Rapporti ISTISAN 09/17 - Attività
- Page 121 and 122:
Rapporti ISTISAN 09/17 sanitaria pe
- Page 123 and 124:
Rapporti ISTISAN 09/17 Reparto Pato
- Page 125 and 126:
Rapporti ISTISAN 09/17 - Punto di r
- Page 127 and 128:
Rapporti ISTISAN 09/17 di CRL for E
- Page 129 and 130:
Rapporti ISTISAN 09/17 Mediante l
- Page 131 and 132:
Rapporti ISTISAN 09/17 gestione e i
- Page 133 and 134:
Rapporti ISTISAN 09/17 Il Reparto p
- Page 135 and 136:
Rapporti ISTISAN 09/17 - Reparto de
- Page 137 and 138:
Rapporti ISTISAN 09/17 - Prosecuzio
- Page 139 and 140:
Rapporti ISTISAN 09/17 - Studio di
- Page 141 and 142:
Rapporti ISTISAN 09/17 - Monitoragg
- Page 143 and 144:
Rapporti ISTISAN 09/17 - Technology
- Page 145 and 146:
Rapporti ISTISAN 09/17 contesto, il
- Page 147 and 148:
Rapporti ISTISAN 09/17 innovativi p
- Page 149 and 150:
Rapporti ISTISAN 09/17 ruolo di Tat
- Page 151 and 152:
Rapporti ISTISAN 09/17 CENTRO NAZIO
- Page 153 and 154:
Rapporti ISTISAN 09/17 ai lavori de
- Page 155 and 156:
Rapporti ISTISAN 09/17 Nell’ambit
- Page 157 and 158:
Rapporti ISTISAN 09/17 sullo svilup
- Page 159 and 160:
Rapporti ISTISAN 09/17 Nello stesso
- Page 161 and 162:
Rapporti ISTISAN 09/17 Avvio delle
- Page 163 and 164:
Rapporti ISTISAN 09/17 di Sorveglia
- Page 165 and 166:
Rapporti ISTISAN 09/17 - Studio sul
- Page 167 and 168:
Rapporti ISTISAN 09/17 - sviluppo e
- Page 169 and 170:
Rapporti ISTISAN 09/17 l’attivit
- Page 171 and 172:
Rapporti ISTISAN 09/17 laboratori d
- Page 173 and 174:
Rapporti ISTISAN 09/17 - Attività
- Page 175 and 176:
Rapporti ISTISAN 09/17 Gli strument
- Page 177 and 178:
Rapporti ISTISAN 09/17 - è stata o
- Page 179 and 180:
Rapporti ISTISAN 09/17 grande la di
- Page 181 and 182:
Rapporti ISTISAN 09/17 - Partecipaz
- Page 183 and 184:
Rapporti ISTISAN 09/17 in particula
- Page 185 and 186:
Rapporti ISTISAN 09/17 - alla produ
- Page 187 and 188:
Rapporti ISTISAN 09/17 L’Osservat
- Page 189 and 190:
Rapporti ISTISAN 09/17 - Depressive
- Page 191 and 192:
Rapporti ISTISAN 09/17 partecipazio
- Page 193 and 194:
Rapporti ISTISAN 09/17 - Programma
- Page 195 and 196:
Rapporti ISTISAN 09/17 - Studio di
- Page 197 and 198:
Rapporti ISTISAN 09/17 - Messa a pu
- Page 199 and 200:
Rapporti ISTISAN 09/17 condotto lo
- Page 201 and 202:
Rapporti ISTISAN 09/17 CENTRO NAZIO
- Page 203 and 204:
Rapporti ISTISAN 09/17 - Per quanto
- Page 205 and 206:
Rapporti ISTISAN 09/17 - Fornisce,
- Page 207 and 208:
Rapporti ISTISAN 09/17 CENTRO NAZIO
- Page 209 and 210:
Rapporti ISTISAN 09/17 nella parte
- Page 211 and 212:
Rapporti ISTISAN 09/17 Official Con
- Page 213 and 214:
Rapporti ISTISAN 09/17 CENTRO NAZIO
- Page 215 and 216:
Rapporti ISTISAN 09/17 donazione e
- Page 217 and 218:
Rapporti ISTISAN 09/17 “PERformar
- Page 219 and 220:
Rapporti ISTISAN 09/17 CENTRO NAZIO
- Page 221 and 222:
Rapporti ISTISAN 09/17 materia. Il
- Page 223 and 224:
Rapporti ISTISAN 09/17 SERVIZIO BIO
- Page 225 and 226:
Rapporti ISTISAN 09/17 le proteine
- Page 227 and 228:
Rapporti ISTISAN 09/17 quindi suppo
- Page 229 and 230:
Rapporti ISTISAN 09/17 - Active dir
- Page 231 and 232:
Rapporti ISTISAN 09/17 o Sviluppo e
- Page 233 and 234:
Rapporti ISTISAN 09/17 - Fornitura
- Page 235 and 236:
Rapporti ISTISAN 09/17 diffusione d
- Page 237 and 238:
Rapporti ISTISAN 09/17 - iniziative
- Page 239 and 240:
Rapporti ISTISAN 09/17 divulgazione
- Page 241 and 242:
Rapporti ISTISAN 09/17 gradimento t
- Page 243 and 244:
Rapporti ISTISAN 09/17 l’Eastern
- Page 245 and 246:
Rapporti ISTISAN 09/17 - Si è conc
- Page 247 and 248:
Rapporti ISTISAN 09/17 - valutazion
- Page 249 and 250:
Rapporti ISTISAN 09/17 contiene una
- Page 251 and 252:
Rapporti ISTISAN 09/17 DIREZIONE GE
- Page 253 and 254:
Rapporti ISTISAN 09/17 delle proble
- Page 255 and 256:
Rapporti ISTISAN 09/17 - Commission
- Page 257 and 258:
Rapporti ISTISAN 09/17 L’attivit
- Page 259 and 260:
Rapporti ISTISAN 09/17 conteggi rel
- Page 261 and 262:
Rapporti ISTISAN 09/17 - Ufficio pe
- Page 263 and 264:
Rapporti ISTISAN 09/17 determinazio
- Page 265 and 266:
Rapporti ISTISAN 09/17 - Gestioni c
- Page 267 and 268:
Rapporti ISTISAN 09/17 Ufficio VI.
- Page 269 and 270:
Rapporti ISTISAN 09/17 Tutta questa
- Page 271 and 272:
Rapporti ISTISAN 09/17 alle loro di
- Page 273 and 274:
Rapporti ISTISAN 09/17 amministrazi
- Page 275 and 276:
Rapporti ISTISAN 09/17 approvate da
- Page 277 and 278:
Rapporti ISTISAN 09/17 e/o con rice
- Page 279 and 280:
Rapporti ISTISAN 09/17 delibera del
- Page 281 and 282:
Rapporti ISTISAN 09/17 Si segnala,i
- Page 283 and 284:
Rapporti ISTISAN 09/17 L’applicaz
- Page 285 and 286:
Rapporti ISTISAN 09/17 PARTE 3 Prog
- Page 287 and 288:
Rapporti ISTISAN 09/17 Accordo di c
- Page 289 and 290:
Rapporti ISTISAN 09/17 quello di so
- Page 291 and 292:
Rapporti ISTISAN 09/17 scala in fut
- Page 293 and 294:
Rapporti ISTISAN 09/17 innovative n
- Page 295 and 296:
Rapporti ISTISAN 09/17 modificazion
- Page 297 and 298:
Rapporti ISTISAN 09/17 terapeutici
- Page 299 and 300:
Rapporti ISTISAN 09/17 Il lavoro di
- Page 301 and 302:
Rapporti ISTISAN 09/17 Università
- Page 303 and 304:
Rapporti ISTISAN 09/17 tali condizi
- Page 305 and 306:
Rapporti ISTISAN 09/17 l’effettua
- Page 307 and 308:
Rapporti ISTISAN 09/17 sito web di
- Page 309 and 310:
Rapporti ISTISAN 09/17 Attività pr
- Page 311 and 312:
Rapporti ISTISAN 09/17 ultimi anni.
- Page 313 and 314:
Rapporti ISTISAN 09/17 Le attività
- Page 315 and 316:
Rapporti ISTISAN 09/17 Resoconto at
- Page 317 and 318:
Rapporti ISTISAN 09/17 Laboratori d
- Page 319 and 320:
Rapporti ISTISAN 09/17 Commissione
- Page 321 and 322:
Rapporti ISTISAN 09/17 di migliorar
- Page 323 and 324:
Rapporti ISTISAN 09/17 attività: i
- Page 325 and 326:
Rapporti ISTISAN 09/17 La Legge att
- Page 327 and 328:
Rapporti ISTISAN 09/17 L’attivit
- Page 329 and 330:
Rapporti ISTISAN 09/17 ospedalieri
- Page 331 and 332:
Rapporti ISTISAN 09/17 È stato inf
- Page 333 and 334:
Rapporti ISTISAN 09/17 - È stata a
- Page 335 and 336:
Rapporti ISTISAN 09/17 Attività pr
- Page 337 and 338:
Rapporti ISTISAN 09/17 Per il punto
- Page 339 and 340:
Rapporti ISTISAN 09/17 - valutazion
- Page 341 and 342:
Rapporti ISTISAN 09/17 focus on Eps
- Page 343 and 344:
Rapporti ISTISAN 09/17 per produtti
- Page 345 and 346:
Rapporti ISTISAN 09/17 In parallelo
- Page 347 and 348:
Rapporti ISTISAN 09/17 In collabora
- Page 349 and 350:
Rapporti ISTISAN 09/17 sindrome di
- Page 351 and 352:
Rapporti ISTISAN 09/17 Sul sito web
- Page 353 and 354:
Rapporti ISTISAN 09/17 Attività pr
- Page 355 and 356:
Rapporti ISTISAN 09/17 che hanno co
- Page 357 and 358:
Rapporti ISTISAN 09/17 L’elaboraz
- Page 359 and 360:
Rapporti ISTISAN 09/17 - raccoglier
- Page 361 and 362:
Rapporti ISTISAN 09/17 - Partecipaz
- Page 363 and 364:
Rapporti ISTISAN 09/17 coppia che p
- Page 365 and 366:
Rapporti ISTISAN 09/17 Salute e del
- Page 367 and 368:
Rapporti ISTISAN 09/17 L’attivit
- Page 369 and 370:
Rapporti ISTISAN 09/17 grave sindro
- Page 371 and 372:
Rapporti ISTISAN 09/17 maggiore di
- Page 373 and 374:
Rapporti ISTISAN 09/17 informazioni
- Page 375 and 376: Rapporti ISTISAN 09/17 ultimo, v) s
- Page 377 and 378: Rapporti ISTISAN 09/17 - Immunità
- Page 379 and 380: Rapporti ISTISAN 09/17 Sviluppo di
- Page 381 and 382: Rapporti ISTISAN 09/17 - valutazion
- Page 383 and 384: Rapporti ISTISAN 09/17 I nostri stu
- Page 385 and 386: Rapporti ISTISAN 09/17 sperimentazi
- Page 387 and 388: Rapporti ISTISAN 09/17 - Valutazion
- Page 389 and 390: Rapporti ISTISAN 09/17 raggiungere
- Page 391 and 392: Rapporti ISTISAN 09/17 Per quanto r
- Page 393 and 394: Rapporti ISTISAN 09/17 convegno ha
- Page 395 and 396: Rapporti ISTISAN 09/17 PARTE 4 Elen
- Page 397 and 398: Rapporti ISTISAN 09/17 ARTICOLI DI
- Page 399 and 400: Rapporti ISTISAN 09/17 Annuzzi G, G
- Page 401 and 402: Rapporti ISTISAN 09/17 Belardelli F
- Page 403 and 404: Rapporti ISTISAN 09/17 Bonadonna L,
- Page 405 and 406: Rapporti ISTISAN 09/17 Caglieri A,
- Page 407 and 408: Rapporti ISTISAN 09/17 Caroli S, Tu
- Page 409 and 410: Rapporti ISTISAN 09/17 quantificati
- Page 411 and 412: Rapporti ISTISAN 09/17 Creti R, Ore
- Page 413 and 414: Rapporti ISTISAN 09/17 Dehò L, Wal
- Page 415 and 416: Rapporti ISTISAN 09/17 Donati S. An
- Page 417 and 418: Rapporti ISTISAN 09/17 controls mel
- Page 419 and 420: Rapporti ISTISAN 09/17 Formichetti
- Page 421 and 422: Rapporti ISTISAN 09/17 Gasparini M,
- Page 423 and 424: Rapporti ISTISAN 09/17 Giansanti D,
- Page 425: Rapporti ISTISAN 09/17 Graziani C,
- Page 429 and 430: Rapporti ISTISAN 09/17 Liumbruno GM
- Page 431 and 432: Rapporti ISTISAN 09/17 Marinaccio A
- Page 433 and 434: Rapporti ISTISAN 09/17 Mercatelli N
- Page 435 and 436: Rapporti ISTISAN 09/17 Muscillo M,
- Page 437 and 438: Rapporti ISTISAN 09/17 Ortiz-Ferron
- Page 439 and 440: Rapporti ISTISAN 09/17 Perego GB, V
- Page 441 and 442: Rapporti ISTISAN 09/17 Piscopo P, M
- Page 443 and 444: Rapporti ISTISAN 09/17 Rainaldi G,
- Page 445 and 446: Rapporti ISTISAN 09/17 Sabelli R, I
- Page 447 and 448: Rapporti ISTISAN 09/17 specific CD4
- Page 449 and 450: Rapporti ISTISAN 09/17 Storani D, T
- Page 451 and 452: Rapporti ISTISAN 09/17 Turrio Balda
- Page 453 and 454: Rapporti ISTISAN 09/17 Weiss EP, Vi
- Page 455 and 456: Rapporti ISTISAN 09/17 Buratti FM,
- Page 457 and 458: Rapporti ISTISAN 09/17 Maggini M, R
- Page 459 and 460: Rapporti ISTISAN 09/17 RAPPORTI TEC
- Page 461 and 462: Rapporti ISTISAN 09/17 Chotro MG, A
- Page 463 and 464: Rapporti ISTISAN 09/17 Gaita A, Bar
- Page 465 and 466: Rapporti ISTISAN 09/17 Mancini L. S
- Page 467 and 468: Rapporti ISTISAN 09/17 Soggiu ME, B
- Page 469 and 470: Rapporti ISTISAN 09/17 Baldissera S
- Page 471 and 472: Rapporti ISTISAN 09/17 Bortolin E,
- Page 473 and 474: Rapporti ISTISAN 09/17 Carnevale D,
- Page 475 and 476: Rapporti ISTISAN 09/17 Conti S, Kan
- Page 477 and 478:
Rapporti ISTISAN 09/17 De Castro P.
- Page 479 and 480:
Rapporti ISTISAN 09/17 Donelli G. R
- Page 481 and 482:
Rapporti ISTISAN 09/17 Flore R, Ger
- Page 483 and 484:
Rapporti ISTISAN 09/17 Grande S, Lu
- Page 485 and 486:
Rapporti ISTISAN 09/17 campioni bio
- Page 487 and 488:
Rapporti ISTISAN 09/17 Marinozzi F,
- Page 489 and 490:
Rapporti ISTISAN 09/17 experimental
- Page 491 and 492:
Rapporti ISTISAN 09/17 Pinto A, Cic
- Page 493 and 494:
Rapporti ISTISAN 09/17 Santarsiero
- Page 495 and 496:
Rapporti ISTISAN 09/17 Tait S, La R
- Page 497 and 498:
Rapporti ISTISAN 09/17 Valsecchi S,
- Page 499:
La riproduzione parziale o totale d